The New York Times looks at the rising campaign to “educate” the public and physicians about “binge eating disorder” and how to “treat” it with an amphetamine.
“As Shire introduces an ambitious campaign to promote Vyvanse but also to raise awareness about the disorder, some are saying the company is going too far to market a drug, a type of amphetamine, that is classified by the federal government as having a high potential for abuse,” reports the Times. “Shire’s track record is adding to the worry: The company helped put another once-stigmatized condition — attention deficit hyperactivity disorder — on the medical map and made billions of dollars from the sale of drugs, like Vyvanse and Adderall, to treat it. In recent years, federal officials have cited the company for inappropriately marketing Vyvanse and other A.D.H.D. drugs.”
Shire, Maker of Binge-Eating Drug Vyvanse, First Marketed the Disease (New York Times, February 24, 2015)